NCT01449812View on ClinicalTrials.gov

Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine

PHASE3CompletedINTERVENTIONAL
Enrollment

831

Participants

Timeline

Start Date

October 1, 2011

Primary Completion Date

January 16, 2012

Study Completion Date

January 16, 2012

Conditions
Acellular PertussisTetanusDiphtheriaHaemophilus Influenzae Type b
Interventions
BIOLOGICAL

Infanrix+Hib™

Intramuscular, one dose

BIOLOGICAL

Poliorix™

Intramuscular, one dose

Trial Locations (2)

543002

GSK Investigational Site, Wuzhou

543100

GSK Investigational Site, Wuzhou

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01449812 - Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine | Biotech Hunter | Biotech Hunter